Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4

2 hours ago 2

Soumya Eswaran

Fri, March 27, 2026 astatine 11:16 AM CDT 3 min read

ClearBridge Investments, an concern absorption company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Strategy underperformed the Russell 2000 Growth Index successful the 4th quarter, aft a beardown archetypal 3 quarters of 2025. Market’s overreactions to net disappointments successful the exertion assemblage and a biotech rally drove the comparative underperformance of the Strategy successful the quarter. In a volatile year, dominated by a constrictive acceptable of themes, the tiny caps failed to outperform ample caps, echoing the past 2 years, though broadening appears to beryllium emerging. Heading to 2026, the Strategy is optimistic astir the favorable backdrop for small-cap maturation stocks pursuing years of constrictive marketplace enactment and show disparities. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, ClearBridge Small Cap Growth Strategy highlighted stocks similar Dyne Therapeutics, Inc. (NASDAQ:DYN). Dyne Therapeutics, Inc. (NASDAQ:DYN) is simply a clinical-stage neuromuscular illness institution that focuses connected processing therapeutics for neuromuscular diseases. On March 26, 2026, Dyne Therapeutics, Inc. (NASDAQ:DYN) closed astatine $18.55 per share. One-month instrumentality of Dyne Therapeutics, Inc. (NASDAQ:DYN) was 15.69%, and its shares gained 57.82% implicit the past 52 weeks. Dyne Therapeutics, Inc. (NASDAQ:DYN) has a marketplace capitalization of $2.98 billion.

ClearBridge Small Cap Growth Strategy stated the pursuing regarding Dyne Therapeutics, Inc. (NASDAQ:DYN) successful its 4th fourth 2025 capitalist letter:

"2025 was different progressive twelvemonth for caller thought generation, portion we besides endeavored to support our merchantability subject successful businesses wherever fundamentals person changed oregon idiosyncratic catalysts are lacking. With a gradual reopening of superior markets, on with dynamic trends crossed galore extremity markets, we proceed to find ample opportunities to place high-quality investments crossed the spectrum of maturation from compounders to hyper-growers.

During the 4th fourth we initiated 4 caller communal banal investments: Protagonist Therapeutics, Simpson Manufacturing Company, BETA Technologies, and Dyne Therapeutics, Inc. (NASDAQ:DYN) .

Dyne Therapeutics is simply a biotechnology institution processing precocious signifier RNA-based therapies for muscular dystrophy conditions. With constricted existing attraction options and encouraging aboriginal data, upcoming objective milestones correspond meaningful imaginable worth instauration opportunities."

Read Entire Article